Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

agreement with Abbott regarding payment of the note on terms that will enable it to continue commercializing urokinase. Upon execution, the Company will hold full title to the asset including the remaining urokinase inventory and will receive 100% of proceeds generated from future sales. The Company expects to close this transaction in the second quarter of 2008.

Financial Results

Revenue for the fourth quarter ended December 31, 2007 rose to $2.7 million from $0.7 million for the fourth quarter ended December 31, 2006. Full year 2007 revenue increased to $8.4 million from $1.3 million for the full year 2006. Sales of urokinase, which ImaRx began commercializing in October 2006, drove the revenue increase for the most recent quarter and full year.

Net loss for the fourth quarter of 2007 was $2.2 million compared to net income of $10.7 million in the year ago period. This change was primarily a result of a $16.1 million gain on extinguishment of debt associated with the relinquishment of the recombinant thrombolytic drug assets to Abbott in the fourth quarter of 2006. Net loss per share attributable to common shareholders of $0.24 for the fourth quarter of 2007 was based on weighted average shares of approximately 9.1 million, compared to net income per share attributable to common shareholders of $3.94 in the fourth quarter of 2006 based on weighted average shares of approximately 2.6 million.

Net loss for the full year 2007 was $8.8 million compared to $0.7 million for the full year 2006. This change was primarily a result of a $16.1 million gain on extinguishment of debt associated with the relinquishment of the recombinant thrombolytic drug assets to Abbott in the fourth quarter of 2006, partially offset by increased sales of urokinase in 2007 over 2006. Net loss per share attributable to common shareholders of $3.16 for the full year 2007 was based on weighted average shares of approximately 5.9 million compared to a net loss per sha
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader ... genetic test built upon research from their published P.A.I.N. ... provide physicians with an objective way to understand theirs ... between individuals. With this new test, physicians will be ... predisposition that will affect their pain tolerance. , The ...
(Date:9/30/2014)... Basel, Switzerland (PRWEB) September 30, 2014 ... advanced software solutions for drug discovery and ... the FUNGITECT consortium has chosen Genedata Selector ... next-generation sequencing (NGS) data. FUNGITECT is a ... of invasive fungal diseases via individualized anti-fungal ...
(Date:9/30/2014)... iLab Solutions announced the results of ... which focuses on core facility operations, growth and utilization ... today. , In its 4th year running, a number ... the year-over-year decrease in the percentage of revenue that ... feeling the constraints of this trend. When asked, “What ...
(Date:9/30/2014)... September 30, 2014 Rainbow Scientific, ... research products, recently opened an online store to ... culture product lines developed and manufactured by Biological ... store include Biological Industries’ Nutristem® serum-free, xeno-free reagents ... embryonic stem cell (hESC) culture. , The ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2
... professionals will have the opportunity hear about the latest in ... Wisconsin Dairyland HIMSS Fall Technology Conference . , ,The ... in La Crosse, will be split into two parts. The ... a golf outing and a riverboat cruise, gatherings where the ...
... Tascon Group has launched the Tascon Business Analyst online, offering ... , ,The Business Analyst is being offered as a licensed ... ,The program is based on a business valuation method developed ... system known as the optimization method. , ,"It is based ...
... - John McNeish gives it a light-hearted spin when ... trusted institutions in America. , ,"The polls say only 3 ... view of drug companies," Pfizer executive McNeish told a group ... Research Park last week. "That means only one or two ...
Cached Biology Technology:Conference will review healthcare IT 2The 3 percent solution: Unpopular drug companies still push discovery 2The 3 percent solution: Unpopular drug companies still push discovery 3
(Date:9/30/2014)... getting pregnanteven with IVF? Here,s some hope: A new ... The FASEB Journal , explains how scientists ... as PAWP, which induced embryo development in human and ... development by the sperm cell during fertilization. , "We ... major paradigm shift in our understanding of human fertilization ...
(Date:9/30/2014)... 2014  Spectra Automation, a trusted supplier ... and power generation industries, announced today the ... an easy-to-use and cost-effective data collection, analysis ... laboratories. Most upstream process ... systems. Accessing and consolidating data from these ...
(Date:9/30/2014)... People who suffer from asthma may think there,s ... asthma besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the ... and Immunology (ACAAI), asthma sufferers can learn lessons about ... described in the Annals article improved her asthma once ...
Breaking Biology News(10 mins):Synthetic sperm protein raises the chance for successful in vitro fertilization 2Spectra Automation Introduces RECONN Bioprocess Manager 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... Shelbyville Police Department, WALL, N.J., March ... BKYI), a leader in finger-based biometric,identification and ... of a contract from the Shelbyville, IN ... data system. Using,MobileCop(TM) software, BIO-key,s wireless messaging ...
... Using Piecewise Smooth Subdivision Surface Provides Both ... Patients, SEATTLE, April 8, 2008 Three dimensional ... insights,that help cardiologists diagnose and treat patients with tetralogy ... American Journal,Cardiology (2008; Vol. 101, Issue 1, 107-113)., ...
... tropical parasitic sickness that currently affects more than 16 million ... the tropical areas of South and Central America. And yet ... toxic and causes serious side effects. Now, new research ... identified for the first time a sensitive method for testing ...
Cached Biology News:BIO-key(R) Receives New Mobile Data Contract Award From Indiana Police Agency 2BIO-key(R) Receives New Mobile Data Contract Award From Indiana Police Agency 3Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3Research identifies first method for testing, assessing drug treatments for Chagas' disease 2Research identifies first method for testing, assessing drug treatments for Chagas' disease 3
... RCT series of refrigerated cold traps offers ... of low volatility/aqueous solvents or high volatility ... other vacuum concentrators/centrifugal evaporators. Also used for ... such as used in electron microscopes. Can ...
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
... Orbital Shakers combine high durability and ... power. The patented triple-counterbalanced heavy-duty ... to run with heavy out-of-balance loads. ... reduces contamination. The heavy stainless ...
The Holten mini vertical flow workbench provides a particle-free environment for sample protection against airborne contaminants....
Biology Products: